FOXP3 and non-small cell lung carcinoma: Koh et al. (160) analyzed the correlation between Foxp3+ T cells with clinical outcomes before and after anti-PD-1 immunotherapy in patients with advanced NSCLC and found that a higher frequency of blood Tregs 1 week after immunotherapy was associated with prolonged PFS and OS when compared with patients with a low frequency of Tregs.